Update on Phase 2a Clinical Trial Results of RXI-109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars and Keloids
|
|
- Sharleen Jackson
- 5 years ago
- Views:
Transcription
1 Update on Phase 2a Clinical Trial Results of RXI-109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars and Keloids Presenter: Pamela A. Pavco, PhD Chief Development Officer RXi Pharmaceuticals Corporation June 9, 2015 FC-07 Wound Healing 23 rd World Congress of Dermatology
2 Overview and Learning Objectives At the conclusion of this talk you will understand: the potential for RNA interference as a dermal therapeutic the key role of CTGF in dermal scarring and keloid formation results of initial Phase 1 and 2a trials with RXI-109, a proprietary, self-delivering RNAi compound that targets CTGF key learnings from the early and ongoing RXI-109 trials, and the next steps for clinical studies with RXI-109.
3 Therapeutic Development of RNA Interference
4 First Development Area: Dermal Scarring Addressing significant unmet medical need with large market potential Targeting Connective Tissue Growth Factor (CTGF) CTGF plays a key role in tissue regeneration & repair, overexpression leads to scarring Unmet need with limited competition for truly effective therapies No prescription drugs approved Trials initiated with RXi s first clinical candidate: RXI-109 RXI-109 is an sd-rxrna compound developed to reduce dermal and retinal scarring Large market in scar prevention/revision 42.3 million surgical procedures per year in the United States* 177,000 scar revision surgeries per year in the United States** *US anti-scarring market The Nemetz Group December 2009 **2014 Plastic Surgery Statistics Report, American Society of Plastic Surgeons Type of Skin Surgery Cosmetic Reconstructive Moles Trauma Elective (office) Elective (hospital) TOTAL Annual Number of Procedures 6.0 million 3.9 million 3.4 million 9.0 million 9.6 million 10.4 million 42.3 million
5 Key Role of Connective Tissue Growth Factor (CTGF) CTGF in Dermal Scarring Tissue Regeneration Connective Tissue Growth Factor Central player in the balance between healthy healing and excessive fibrosis Excessive Fibrosis RXI-109 Cellular Effects Collagen Deposition Adhesion Migration Proliferation Differentiation Pathologic Effects Pulmonary Fibrosis Acute Spinal Injury Dermal Scarring Restenosis Ocular Scarring Liver Fibrosis
6 Abnormal Skin Healing Hypertrophic Scarring: Raised, often hyperpigmented scar Excess collagen deposition resulting from traumatic injury to deep dermal layers Keloid Disorder: Large, raised scars that grow beyond the boundary of original injury Often hyperpigmented; most common on chest, back, shoulders (areas of tension) & earlobes, usually recur Both have a genetic component More common in persons with darker skin pigmentation (higher Fitzpatrick phototype) Keloid prevalence is <0.1% in Great Britain; 16% in the Congo 1 Hypertrophic scarring can be 40-70% following surgery, higher following burns 2 1. Kelly AP Keloids. Dermatol Clin (3): Gauglitz GG Hypertrophic scarring and keloids. Mol Med (2):
7 The Wound Healing Cascade Normal Proliferation Remodeling A Hypertrophic Proliferation Remodeling B C Keloid Proliferation Acute Inflammation post trauma (~2 Weeks) Months 1 Year A Bayat, A et al. BMJ 2003;326; doi: /bmj B Property of RXi Pharmaceuticals C Courtesy of skincareguide.ca
8 Results of Phase 1 Clinical Trials Phase 1: Healthy Volunteers (N = 30 in 2 studies) Dose escalation, dosing via intradermal injection Compared RXI-109 vs. placebo Study 1201: Single dose (at two 2-cm incision sites) Study 1202: Multi-dose (three doses at four 2-cm incision sites) Safety Treatment on Days 1, 8, 15 No significant local effects (local effects of erythema, slight pain), no indication of accumulation, MTD not reached Biomarker Analysis (supports RNAi mechanism of action) Significant dose dependent reduction CTGF protein 84 days post single dose Significant dose dependent reduction of CTGF mrna 3 days post third dose
9 Overview of Phase 2a Clinical Trial Protocols Phase 2a: Treatment with RXI-109 Following Revision Surgery Dosing initiated at start of inflammation or proliferation phase Study 1301: Hypertrophic Scars (3 5 mg/cm; 4, 5, 6 cm) N = 22 patients, 2 cohorts RXI-109 treatment on 4, 5 or 6 cm on one side of scar, vehicle on other Double-blind treatment on Days 1, 8 and 15 (Cohort 1) or Days 14, 21 and 28 (Cohort 2) Pilot Study 1401: Keloids (4 10 mg/cm, up to 3 cm) N = 16 patients, 2 cohorts To Prevent Formation of Dermal Scars or Keloids RXI-109 treatment of one revision site, placebo on other Single-blind treatment on Days 1, 8, 15 and 22 (Cohort 1) or Days 15, 22, 29 and 36 (Cohort 2)
10 RXI : Blinded Panel Evaluation First P2a Study: RXI-109 vs. Placebo after Scar Revision Surgery At 3 months, improved results were obtained when treatment with RXI-109 was started two weeks post-surgery 100% 80% p < 0.001* 60% 40% 20% 0% 3 month 3 month Treatment Start Day 1 Treatment Start Day 14 RXI-109 better Placebo better or no difference between sides
11 RXI : Scar Comparison at 3 Months First Phase 2a: RXI Placebo RXI-109 First Two Subjects Subject #1 Subject #2
12 RXI : Scar Comparison at 3 Months Widened scar with keloidal character First Phase 2a: RXI Pre-scar revision surgery PLACEBO 3 months post-scar revision surgery *White dots are markers used in clinical photography. RXI-109
13 Key Learnings from Initial RXI-109 Trials Studies 1301 & 1401: Enrollment and treatment complete 3 doses in 2 weeks for hypertrophic scars; 4 doses in 1 month for keloids Continue follow-up as per protocol (9 and 6 months, respectively) Safety in Phase 2a is similar to Phase 1 Increased dose (amount and number of doses) in Phase 2a Main local effects are mild erythema, slight pain; limited urticaria with no sequelae RXI-109 scored a positive clinical effect on hypertrophic scars at 3 months post surgery Treatment initiating at 2 weeks, at start of proliferation phase of wound healing, is beneficial vs. starting immediately on surgery day Longer treatment duration is indicated Conclusions
14 Next Steps with RXI-109 Study 1402: Hypertrophic Scars Ongoing Dosing initiated at 2 weeks, after the inflammation phase and at start of proliferation phase Increased dosing occasions from 3 to a total of 6 doses Dosing extends well into proliferation phase of wound healing Dosing on Days 14, 21, 28, 35, 56, mg/cm and 5 mg/cm are being compared RXI-109 vs. untreated Enrollment of first group of 20 patients (2 cohorts) almost completed Follow-on Keloid Study Planned Will include an extended dosing schedule
15 Authors and Conflict of Interest Declaration RXi Pharmaceuticals Employees (Marlborough, MA) Pamela Pavco, PhD Karen Bulock, PhD Lyn Libertine, MD Mike Byrne, PhD Margo McKinlay Katherine Holton Laurie Barefoot, CNP, CCRC Pathi Pandarinathan, PhD Geert Cauwenbergh, Dr. Med. Sc. James Cardia, PhD Investigators (funded by RXi Pharmaceuticals to conduct RXI-109 trials) Georgina Nelly Paz, MD, Hospital y Clinica Bendana, Honduras V. Leroy Young, MD, Mercy Research, St. Louis MO (Member of RXi SAB) Ynca Nina Vasquez, MD, Instituto Dermatológico y Cirugía de Piel, DR
Diphenylcyclopropenone Ointment for the Treatment of Common Warts
Poster Presentation #4055 Diphenylcyclopropenone Ointment for the Treatment of Common Warts American Academy of Dermatology 2016 Summer Meeting Boston, MA July 29, 2016 This work was supported by Hapten
More information#1722. Diphencyprone for the treatment of dermatological disorders with an immunological component
#1722 Diphencyprone for the treatment of dermatological disorders with an immunological component 1 William Levis MD, 2 Karen Bulock PhD, 2 James Cardia PhD, 2 Pamela Pavco PhD, 2 Geert Cauwenbergh, Dr.
More informationRXi Pharmaceuticals. Bio Investor Forum San Francisco, CA NASDAQ: RXII. October 21, Property of RXi Pharmaceuticals
RXi Pharmaceuticals NASDAQ: RXII Bio Investor Forum San Francisco, CA October 21, 2015 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationRXi Pharmaceuticals. October 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals October 2017 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationRXi Pharmaceuticals. sd-rxrna Demonstrate Robust Efficacy in the Eye. Dr. Geert Cauwenbergh President & CEO OTCQX: RXII. Next Generation in RNAi
RXi Pharmaceuticals sd-rxrna Demonstrate Robust Efficacy in the Eye Next Generation in RNAi Dr. Geert Cauwenbergh President & CEO OTCQX: RXII 2 Forward Looking Statements This presentation contains forward-looking
More informationRXi Pharmaceuticals. Biotech Showcase. San Francisco, CA. January 8, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Biotech Showcase San Francisco, CA January 8, 2018 NASDAQ: RXII Property of RXi Pharmaceuticals Forward Looking Statements This presentation contains forward-looking statements within
More informationClinical Summary. Introduction. What are Scars? There are three main types of scars:
Introduction Clinical Summary Since the introduction of silicone in the early 1980s for the prevention and treatment of hypertrophic & keloid scars, it s therapeutic effects have been well documented in
More informationA Keloid Edge Precut, Preradiotherapy Method in Large Keloid Skin Graft Treatment
A Keloid Edge Precut, Preradiotherapy Method in Large Keloid Skin Graft Treatment WENBO LI, MD, YOUBIN WANG, MD, XIAOJUN WANG, MD, AND ZHIFEI LIU, MD* BACKGROUND Keloids are scars that extend beyond the
More informationA Bio-Oil guide to Scars
A Bio-Oil guide to Scars ii The material in this brochure has been drawn from various sources and collated by Bio-Oil to provide one user-friendly reference on scars. Contents What is a scar? 2 Why do
More informationDIA Oligonucleotide-Based Therapeutics Conference
DIA Oligonucleotide-Based Therapeutics Conference North Bethesda MD October 25-27 Translating PD Biomarkers From Preclinical Studies to Clinical Trials: MRG-201, an Oligonucleotide Mimic of mir- 29, Inhibits
More informationClinical Summary. treatment and prevention of hypertrophic scars have been well documented in the literature.
Introduction: Introduction: Since the introduction of silicone in the early 1980s, its therapeutic effects on predominantly the i, ii treatment and prevention of hypertrophic scars have been well documented
More informationAll surgery carries some uncertainty and risk
Dr Mi chel s on@mi chel s onmd. com All surgery carries some uncertainty and risk While scar revision is normally safe, there is always the possibility of complications. These may include infection, bleeding,
More informationRXi Pharmaceuticals. Building leadership in RNAi and Immunotherapy. Research Note.
Research Note RXi Pharmaceuticals Building leadership in RNAi and Immunotherapy Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com
More informationAbnormal Scars, Management Options
106) Edriss A. S., Měšťák J. Charles University in Prague, First Faculty of Medicine and University Hospital Na Bulovce, Department of Plastic Surgery, Prague, Czech Republic Received April 28, 2008; Accepted
More informationClinical Study Treatment of Mesh Skin Grafted Scars Using a Plasma Skin Regeneration System
Plastic Surgery International Volume 00, Article ID 87448, 4 pages doi:0.55/00/87448 Clinical Study Treatment of Mesh Skin Grafted Scars Using a Plasma Skin Regeneration System Takamitsu Higashimori, Taro
More informationDIFFERENT SCARS AND THEIR MANAGEMENT
DIFFERENT SCARS AND THEIR MANAGEMENT Dr R. Newaj Specialist Dermatologist MBBCh (Wits) FCDerm (SA) Arwyp medical centre, Kemptonpark and Intercare Irene, Centurion COMMON CAUSES OF WOUNDS AND INJURIES
More informationChapter 1. General introduction and outine of the thesis
Chapter 1 General introduction and outine of the thesis Introduction Skin anatomy Skin covers the entire body and provides a barrier between the body and the outside world through its mechanical as well
More informationSix-Month Safety Results of Calcium Hydroxylapatite for Treatment of Nasolabial Folds in Fitzpatrick Skin Types IV to VI
Six-Month Safety Results of Calcium Hydroxylapatite for Treatment of Nasolabial Folds in Fitzpatrick Skin Types IV to VI ELLEN S. MARMUR, MD, SUSAN C. TAYLOR, MD, y PEARL E. GRIMES, MD, z CHARLES M. BOYD,
More informationYOUR KELO-COTE GUIDE TO LIVING WITH YOUR SURGICAL SCAR
YOUR KELO-COTE GUIDE TO LIVING WITH YOUR SURGICAL SCAR CONTENTS WHAT IS THE DEFINITION OF A SCAR? 3 WHAT TYPES OF SCARS ARE THERE? 3 SCARS RESULTING FROM SURGERY 4 HOW COMMON ARE SCARS? 4 WHY DO THEY FORM?
More informationThis chapter gives background information about the scarring process. Treatment options for problematic scars are also discussed.
Chapter 15 SCAR FORMATION KEY FIGURES: Hypertrophic scar Buried dermal suture This chapter gives background information about the scarring process. Treatment options for problematic scars are also discussed.
More informationSCOPE OF PRACTICE PGY-6 PGY-7 PGY-8
PGY-6 Round on all plastic surgery inpatients every day. Assess progress of patients and identify real or potential problems. Review patients progress with attending physicians daily and participate in
More informationIbrahim Awaisheh ALI KILANY ... Mousa Al-Abbadi
13 Ibrahim Awaisheh ALI KILANY... Mousa Al-Abbadi FACTORS THAT IMPAIR TISSUE REPAIR: Are also called co-morbidities and can act individually or in combination. All can delay repair (causes 2 nd intention
More informationSurgical Excision Followed by Low Dose Rate Radiotherapy in the Management of Resistant Keloids
Original Article 81 Surgical Excision Followed by Low Dose Rate Radiotherapy in the Management of Resistant Keloids Ali Akbar Mohammadi 1 *, Mohammad Mohammadian Panah 2, Mohammad Reza Pakyari 1, Raziyeh
More informationBoston Scientific Corporation Drug-Eluting Stent Program
Boston Scientific Corporation Drug-Eluting Stent Program Copyright 2002 by Scimed Life Systems, Inc. All rights reserved. Program Overview λ λ λ λ λ World Wide Status Restenosis Paclitaxel Polymers Dose
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationEvaluation of the wound healing response post deep dermal heating by fractional RF: INTRAcel
12th symposium of the Association of Korean Dermatologists (2009) 1 Evaluation of the wound healing response post deep dermal heating by fractional RF: INTRAcel Un-Cheol.Yeo, M.D. S&U Dermatologic Clinic,
More informationCLINICAL EVIDENCE Partial and Deep Partial Burns
CLINICAL EVIDENCE Partial and Deep Partial Burns Endoform helps to improve re-epithelialization after burn injuries Endoform helps to facilitate tissue granulation and epithelialization in partial and
More informationDual wavelength (1540nm nm) mixed technology for fractional resurfacing in skin rejuvenation Background
Dual wavelength (1540nm + 10600 nm) mixed technology for fractional resurfacing in skin rejuvenation Dr. Paolo Sbano, M.D. Specialist in Dermatology and Venereology Department of Dermatology of Belcolle
More informationDepartment of Dermatology Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok, THAILAND
The efficacy of the treatment of abdominal cellulite and skin tightening with a Venus Freeze (MP) 2 - A pilot study Rungsima Wanitphakdeedecha, MD, MA, MSc Department of Dermatology Faculty of Medicine
More informationVicore Pharma AB. Audiocast, October 2, Presentation by Per Jansson, CEO and Ulrike Muscha Steckelings, CSO
Vicore Pharma AB Audiocast, October 2, 2017 1 Presentation by Per Jansson, CEO and Ulrike Muscha Steckelings, CSO FORWARD-LOOKING STATEMENTS This presentation may contain certain forward-looking statements
More informationPracaSil -Plus. Scientific Publications. The original topical silicone base for scars and other skin conditions. Provided by
PracaSil -Plus The original topical silicone base for scars and other skin conditions. Scientific Publications Provided by PracaSil -Plus TECHNICAL REPORT In Vitro Evaluation of the Safety Profile of PracaSil
More informationKeloids. Disclaimer. Multimedia Health Education
Disclaimer This movie is an educational resource only and should not be used to manage your health. All decisions about the management of must be made in conjunction with your Physician or a licensed healthcare
More informationKnowledge-Powered Medicine
mohs surgery A patient guide to specialized treatment for skin cancer Knowledge-Powered Medicine upgdocs.org/dermatology upgdocs.org/dermatology A patient guide Preparing for Mohs Surgery > What is Mohs
More informationNovan Provides Update on SB414 Inflammatory Skin Disease Development Program
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program SB414 Nitric Oxide-Releasing Cream Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting
More informationSmart Solutions for Serious Wounds. An advanced bilayer dermal regeneration matrix FDA approved for the treatment of diabetic foot ulcers.
Smart Solutions for Serious Wounds An advanced bilayer dermal regeneration matrix FDA approved for the treatment of diabetic foot ulcers. A New Approach to Diabetic Foot Ulcer Care Supported by Over Two
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationidentifying & treating Structural Skin Damage
identifying & treating Structural Skin Damage How Collagen and Elastin are Formed The dermis is comprised of three layers: the papillary dermis, the reticular dermis, and the subcutaneous dermis. The process
More informationAfter this presentation and discussion, the participants should be able to:
Tissue Repair Robert F. Diegelmann, Ph.D. OBJECTIVES After this presentation and discussion, the participants should be able to: 1. Define the biochemical responses to tissue injury 2. Describe the mechanisms
More informationFor more information about how to cite these materials visit
Author(s): Gerald Abrams, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Non-commercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
More informationClinical Efficacy and Statistical Evaluation of INTRAcel Treatment
Unique technology of Fractional RF Micro-needles TM 1 Clinical Efficacy and Statistical Evaluation of INTRAcel Treatment Takashi Takahashi, M.D. Dermatologist Takahashi Clinic Shibuya, Tokyo, Japan BACKGROUND:
More informationMohs. Micrographic Surgery. For Treating Skin Cancer
Mohs Micrographic Surgery For Treating Skin Cancer Skin Cancer Basics Skin cancer is common. Over the past three decades, more people have had skin cancer than all other cancers combined. Each year in
More informationMedical Discovery. Delivers Hope. H100 Topical Treatment for Peyronie s Disease
Medical Discovery Delivers Hope H100 Topical Treatment for Peyronie s Disease What is Peyronie s Disease Peyronie s (pay-roe-neez) disease (PD) is the development of scar tissue (plaque) inside the penis
More informationWhite Paper. Wound Closure
White Paper Table of Contents 1. Introduction... 3 2. Primary Endpoint:... 3 3. Secondary Endpoint: Cosmetic Outcome... 4 4. Safety Endpoints... 4 5. Control Group... 5 6. Patient Recruitment and Retention...
More informationComparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids
Original Article Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids Muhammad Uzair, Ghazala Butt, Khawar Khurshid, Sabrina Suhail Pal Department of Dermatology,
More informationIontophoresis Platform Safely and Effectively Delivers Dexamethasone to Manage Post Operative Inflammation and Pain Following Cataract Surgery.
Poster #33516 Iontophoresis Platform Safely and Effectively Delivers Dexamethasone to Manage Post Operative Inflammation and Pain Following Cataract Surgery. JEFFREY H. LEVENSON, MD 1 (PRESENTING AUTHOR);
More informationHealing & Repair. Tissue Regeneration
Healing & Repair Dr. Srikumar Chakravarthi Repair & Healing: Are they same? Repair :Regeneration of injured cells by cells of same type, as with regeneration of skin/oral mucosa (requires basement membrane)
More informationFast acting Complex formulations Clinically proven ingredients Economical price
Fast acting Complex formulations Clinically proven ingredients Economical price UK s top selling Professional Skincare PharmaClinix Ltd, Unit 3 Issigonis House, Cowley Road, London, W3 7UN, UK Scar Repairex
More informationEvaluation of the wound healing response post - deep dermal heating by fractional RF: INTRACEL
12th symposium of the Association of Korean Dermatologists (2009) 1 Evaluation of the wound healing response post - deep dermal heating by fractional RF: INTRACEL Un-Cheol.Yeo, MD S&U Dermatologic Clinic,
More informationCastle Creek Pharmaceuticals
Castle Creek Pharmaceuticals Dermatology Summit Entrepreneurial Showcase 2018 Michael Derby, CEO January 7, 2018 Castle Creek Pharma Driving innovation in dermatology We are a high-growth biotech company
More informationAnimal Models of Scarring: The Rabbit Ear Model and its Translational Relevance. Thomas A. Mustoe Northwestern University Chicago,IL USA
Animal Models of Scarring: The Rabbit Ear Model and its Translational Relevance Thomas A. Mustoe Northwestern University Chicago,IL USA Important Regulators of Scarring Genetics (racial characteristics,
More informationSPECIAL TOPIC. AboutSkin Dermatology & DermSurgery, Greenwood Village, CO b. The Aesthetic Clinique, Destin, FL c
November 2016 611 Volume 15 Issue 11 Copyright 2016 ORIGINAL ARTICLES SPECIAL TOPIC Multi-Center Pilot Study to Evaluate the Safety Profile of High Energy Fractionated Radiofrequency With Insulated Microneedles
More informationi-bodies a new class of protein therapeutics to treat fibrosis
i-bodies a new class of protein therapeutics to treat fibrosis BIOSHARES JULY 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is subject
More information2018 Investor Presentation
2018 Investor Presentation FORWARD LOOKING STATEMENT This presentation includes forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform
More informationIs Avotermin Safe and Effective Treatment for Scar Improvement in Healthy Males and Females?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Avotermin Safe and Effective Treatment
More informationRSM. Indications For Use
NEXT GENERATION SOLUTIONS RSM PATRIOT-RSM Amniotic Allograft Membrane is a human placental-based tissue product. The membrane forms a protective covering over the wound while providing the key components
More informationBreast reduction surgery reduction mammaplasty Is it right for me? What to expect during your consultation Be prepared to discuss:
This guide is for women who are considering having an operation to lift their breasts. We advise that you talk to a plastic surgeon and only use this information as a guide to the procedure. Breast reduction
More informationA Pilot Study to Investigate the Efficacy of Tobramycin Dexamethasone Ointment in Promoting Wound Healing
Dermatol Ther (2012) 2:12 DOI 10.1007/s13555-012-0012-8 ORIGINAL RESEARCH A Pilot Study to Investigate the Efficacy of Tobramycin Dexamethasone Ointment in Promoting Wound Healing Rachel Andrew Gwendolyn
More informationAugmentation of Atrophic Deprssed Scars Utilizing the Deepithelialized Scar Tissue Itself
Med. J. Cairo Univ., Vol. 82, No. 2, June: 123-127, 2014 www.medicaljournalofcairouniversity.net Augmentation of Atrophic Deprssed Scars Utilizing the Deepithelialized Scar Tissue Itself WAEL SAADELDEEN,
More informationNO MORE NEWS AN EVIDENCE BASED APPROACH ON LASERS IN SKIN OF COLOR PATIENTS DR. EDUARDO WEISS, M.D., FAAD
NO MORE NEWS AN EVIDENCE BASED APPROACH ON LASERS IN SKIN OF COLOR PATIENTS DR. EDUARDO WEISS, M.D., FAAD KEY POINTS Hispanics/Latinos are the fastest growing segment of the skin of color population Use
More informationClinical Trial of BCT KoCarbonAg Silver Bandage
Clinical Trial of BCT KoCarbonAg Silver Bandage A Comparative Efficacy and Safety Study between Bio-Medical Carbon Technology Silver Bandage and Aquacel Ag Dressing In Obstetrical and Gynecological Post-Operation
More informationThe choice for aesthetic and functional results in loss of substances 1 SKIN EXPERTISE WITH A NEW COLLAGEN TECHNOLOGY
The choice for aesthetic and functional results in loss of substances 1 SKIN EXPERTISE WITH A NEW COLLAGEN TECHNOLOGY SYMATESE: OUR EXPERTISE IN THE FIELD OF COLLAGEN AND SKIN SYMATESE GROUP is recognized
More informationTissue repair. (3&4 of 4)
Tissue repair (3&4 of 4) What will we discuss today: Regeneration in tissue repair Scar formation Cutaneous wound healing Pathologic aspects of repair Regeneration in tissue repair Labile tissues rapid
More informationDaryl Mossburg, BSN RN Clinical Specialist Sciton, Inc.
Daryl Mossburg, BSN RN Clinical Specialist Sciton, Inc. What is Halo? Indications for Use Physics/Science Patient Selection & Contraindications Treatment Overview & Guidelines Halo Technology/System Overview
More informationAdvanced Skin Needling with Dermapen. Tony Chu Dermatology Unit Hammersmith Hospital London, UK
Advanced Skin Needling with Dermapen Tony Chu Dermatology Unit Hammersmith Hospital London, UK Applications Atrophic scarring face, back and chest Acne and chicken pox Facial rejuvenation Treatment of
More informationBiologics in ACL: What s the Data?
Biologics in ACL: What s the Data? Jo A. Hannafin, M.D., Ph.D. Professor of Orthopaedic Surgery, Weill Cornell Medical College Attending Orthopaedic Surgeon and Senior Scientist Sports Medicine and Shoulder
More informationIs the Use of Triamcinolone (TAC) in Combination with 5-Fluorouracil (5-FU) More Effective than TAC Alone in the Treatment of Keloid Scars?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is the Use of Triamcinolone (TAC)
More informationSTUDY. Prevention of Scar Spread on Trunk Excisions. Kevin F. Kia, MD; Molly V. Burns, MD; Travis Vandergriff, MD; Sarah Weitzul, MD
STUDY Prevention of Scar Spread on Trunk Excisions A Rater-Blinded Randomized Controlled Trial Kevin F. Kia, MD; Molly V. Burns, MD; Travis Vandergriff, MD; Sarah Weitzul, MD Importance: Wounds that heal
More informationBACKGROUND. Pathologic Scars
Medical and Rehabilitation Innovations Laser Therapy for Hypertrophic Scars & Keloids in Burns 2016 BACKGROUND Laser therapy has recently emerged as a promising option for treatment of hypertrophic scars
More information9/14/16 PHASES OF HEALING. Mandatory Knowledge LEARNING OBJECTIVE. Understand Phases of Healing in Musculoskeletal Trauma
Mandatory Knowledge LEARNING OBJECTIVE Understand Phases of Healing in Musculoskeletal Trauma LEARNING OBJECTIVE Apply Phases of Healing knowledge in the evaluation and treatment of musculoskeletal complaints
More informationSurgical Wounds & Incisions
Surgical Wounds & Incisions A Comprehensive Review Assessment & Management Alex Khan APRN ACNS-BC MSN CWCN CFCN WCN-C Advanced Practice Nurse / Adult Clinical Nurse Specialist www.woundcarenurses.org 1
More informationForward-looking Statements
NASDAQ:CNAT Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements
More informationTreatment, Rehabilitation and Reconditioning Physiology of Tissue Repair
Treatment, Rehabilitation and Reconditioning Physiology of Tissue Repair PHYSIOLOGY OF TISSUE REPAIR Knowing when it is appropriate to begin rehabilitation and when it is acceptable to return to practice
More informationIn-vivo histopathological study of YouLaser MT interaction with the skin. A laser device emitting combined 1540 and nm wavelengths.
Histology report No. 02/04-12, date April 2nd, 2012 Page 1 In-vivo histopathological study of YouLaser MT interaction with the skin. A laser device emitting combined 1540 and 10600 nm wavelengths. Paolo
More informationArkadin Managed Calls
Arkadin Managed Calls ThromboGenics Conference Call FY 2017 Business Update & Results Thursday 15.03.2018 18u30 CET Speakers: Patrik De Haes, MD, CEO and Dominique Vanfleteren, CFO Call Duration: 19:05
More informationLASER THERAPY FOR PHYSIOTHERAPISTS
BioFlex Laser Therapy presents LASER THERAPY FOR PHYSIOTHERAPISTS Expand your knowledge. Build your practice. Did you know? Laser Therapy is one of the strongest evidence-based therapies according to Clinical
More informationCosmetic Surgery: Breast Reduction
PROCEDURE FACT SHEET PLASTIC SURGERY Cosmetic Surgery: Breast Reduction This guide is for women who are considering having an operation to lift their breasts. We advise that you talk to a plastic surgeon
More informationClinical Policy Title: Laser treatments for hypertrophic scars
Clinical Policy Title: Laser treatments for hypertrophic scars Clinical Policy Number: 17.02.07 Effective Date: June 1, 2017 Initial Review Date: May 19, 2017 Most Recent Review Date: May 19, 2017 Next
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationA Leading HBV Therapeutics Company. Corporate Overview August 2017
A Leading HBV Therapeutics Company Corporate Overview August 2017 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements within the meaning of
More informationIntegra. PriMatrix Dermal Repair Scaffold PATIENT INFORMATION. Questions? Contact us: Clinician: Phone #: In case of emergency, dial 9-1-1
Integra PriMatrix Dermal Repair Scaffold PATIENT INFORMATION Questions? Contact us: Clinician: Phone #: In case of emergency, dial 9-1-1 Your Path to Recovery Your health care provider has chosen to use
More informationSkin lesions & Abrasions
Skin lesions & Abrasions What Are Skin Lesions? A skin lesion is a part of the skin that has an abnormal growth or appearance compared to the skin around it Types of Skin Lesions Two types of skin lesions
More informationUltra Skin Needling. Rejuvenate Supports Collagen Regeneration Scar Improvement. For your best ever skin.
Ultra Skin Needling Rejuvenate Supports Collagen Regeneration Scar Improvement For your best ever skin. Total Skin Rejuvenation What is Skin Needling? Ultra Skin Needling is a skin rejuvenation treatment
More informationLecture 9 - Wound Healing
Lecture 9 - Wound Healing A wound is any disruption to tissue caused by injury The injury is usually traumatic, i.e. physical, mechanical damage to tissue: Wound healing is a special case of acute inflammation
More informationComparative study of dermaroller therapy versus trichloroacetic acid CROSS for the treatment of atrophic acne scars
Original Article Comparative study of dermaroller therapy versus trichloroacetic acid CROSS for the treatment of atrophic acne scars Neerja Puri Consultant Dermatologist, Punjab Health Systems Corporation,
More informationIntroduction from Dr Paul Crozier.
Introduction from Dr Paul Crozier. Retired. Former Medical Director A&E Ascot White Cross Remeura. Medical Director Bodywall Ltd. Repetitive stress on the body whether through emotional and physiological
More informationNeuroMend. Collagen Wrap Conduits. Operative Technique
NeuroMend Collagen Wrap Conduits Operative Technique Stryker NeuroMend Collagen Wrap Conduits Wrap a protective environment around your patients injured peripheral nerves Common Indications The NeuroMend
More informationJURNAL KELOID DISUSUN OLEH : RIDHO OKTIANSAH NPM : RUMAH SAKIT UMUM HAJI MEDAN
JURNAL KELOID DISUSUN OLEH : RIDHO OKTIANSAH NPM : 10310335 RUMAH SAKIT UMUM HAJI MEDAN keloids I. INTRODUCTION Keloids was first proposed by a dermatology named Jean-Louis Albert in France in 1835, but
More informationHypertrophic Scars, Keloid and Homoeopathy
Hypertrophic Scars, Keloid and Homoeopathy DR. RAJNEESH KUMAR SHARMA MD (HOMOEOPATHY) Hypertrophic Scars, Keloid and Homoeopathy Dr. Swati Vishnoi BHMS Dr. Preetika Lakhera BHMS Homoeo Cure Research Institute
More informationSAMPLE. HLTEN406A Undertake basic wound care. Learner resource. HLT07 Health Training Package. Version 2
HLT07 Health Training Package HLTEN406A Undertake basic wound care Learner resource Version 2 Training and Education Support Industry Skills Unit Meadowbank Acknowledgments The TAFE NSW Training and Education
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationA New Approach To Diabetic Foot Ulcers Using Keratin Gel Technology
A New Approach To Diabetic Foot Ulcers Using Keratin Gel Technology Farheen Walid, BA, Shrunjay R. Patel, BSc, Stephanie Wu, DPM, MS Center for Lower Extremity Ambulatory Research (CLEAR), Scholl College
More informationTherapeutic laser treatment is becoming a much more common practice among veterinarians.
Click here to sign-up! Applications Of Therapeutic Laser In Everyday Practice Therapeutic laser treatment is becoming a much more common practice among veterinarians. August 18, 2011 Laser therapy can
More informationCorMatrix ECM Bioscaffold
CorMatrix ECM Bioscaffold REMODEL. REGROW. RESTORE. CorMatrix ECM Bioscaffold provides a natural bioscaffold matrix that enables the body s own cells to repair and remodel damaged cardio-vascular tissue.
More informationPatient Care Information
Patient Care Information A Guide to Healing Diabetic Foot Ulcers Questions? Contact us: Clinician: Phone #: In case of emergency, dial 9-1-1 Dermal Regeneration Matrix Overview Diabetic foot ulcers are
More informationDisclosures. Laser Treatment of Scars. Options for Cutaneous Scarring. Laser Treatment of Erythematous Scars. Laser Scar Revision Scar Type
Fundamentals: Instrumentation, and Skin Type Paul M. Friedman, M.D. Director, Dermatology & Laser Surgery Center Clinical Assistant Professor University of Texas Medical School, Houston, TX Clinical Assistant
More informationNovoSorb BTM. A unique synthetic biodegradable wound scaffold. Regenerating tissue. Changing lives.
NovoSorb BTM A unique synthetic biodegradable wound scaffold Regenerating tissue. Changing lives. Overview NovoSorb BTM is a unique synthetic biodegradable wound scaffold that delivers good cosmetic and
More informationTHE BIOLOGY OF PLATELET-GEL THERAPY
THE BIOLOGY OF PLATELET-GEL THERAPY The synopsis of normal healing includes a well known sequence of coordinated phases. The unique process leading to healing is ontologically partitioned in three sequential
More informationThe Age and Sex Incidence of Keloids / Hypertrophic Scars in Calabar Metropolis, Cross River State from
ISSN 4-308 (Paper) ISSN 5-093X (Online) Vol.4, No.11, 014 The Age and Sex Incidence of Keloids / Hypertrophic Scars in Calabar Metropolis, Cross River State from 001-006 Udo-Affah, G. U.*, Eru, E. M.,
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationMr Zachary Moaveni Plastic Surgeon, Middlemore Hospital. Mr Adam Bialostocki Plastic Surgeon, Tauranga
Mr Zachary Moaveni Plastic Surgeon, Middlemore Hospital Mr Adam Bialostocki Plastic Surgeon, Tauranga Mr. Adam Bialostocki Plastic Surgeon Minor Burns First Aid Remove the burning agent / wet clothes
More information